Next Article in Journal
CHADS2, CHA2DS2ASc, and New ABCD Scores Predict the Risk of Peripheral Arterial Disease in Patients with Sleep Apnea
Previous Article in Journal
Long-Term Outcome of Potential Celiac Disease in Genetically at-Risk Children: The Prospective CELIPREV Cohort Study
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessArticle
J. Clin. Med. 2019, 8(2), 187;

Moscatilin Inhibits Growth of Human Esophageal Cancer Xenograft and Sensitizes Cancer Cells to Radiotherapy

Department of Radiation Oncology, Hsinchu MacKay Memorial Hospital, Hsinchu 30071, Taiwan
Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei 11221, Taiwan
Department of Radiation Oncology in Zhongxing Branch, Taipei City Hospital, Taipei 10341, Taiwan
Department of Medical Research, MacKay Memorial Hospital, New Taipei City 25160, Taiwan
Department of Nursing, MacKay Medical College, New Taipei City 25245, Taiwan
Department of Medical Research, China Medical University Hospital, Taichung 40402, Taiwan
Department of Radiation Oncology, MacKay Memorial Hospital, Taipei 10449, Taiwan
Authors to whom correspondence should be addressed.
Received: 17 December 2018 / Revised: 20 January 2019 / Accepted: 28 January 2019 / Published: 5 February 2019
(This article belongs to the Section Oncology)
Full-Text   |   PDF [2891 KB, uploaded 27 February 2019]   |  


Esophageal cancer prognosis remains poor in current clinical practice. We previously reported that moscatilin can induce apoptosis and mitotic catastrophe in esophageal cancer cells, accompanied by upregulation of polo-like kinase 1 (Plk1) expression. We aimed to validate in vitro activity and Plk1 expression in vivo following moscatilin treatment and to examine the treatment’s radiosensitizing effect. Human esophageal cancer cells were implanted in nude mice. Moscatilin was intraperitoneally (i.p.) injected into the mice. Tumor size, body weight, white blood cell counts, and liver and renal function were measured. Aberrant mitosis and Plk1 expression were assessed. Colony formation was used to measure survival fraction after radiation. Moscatilin significantly suppressed tumor growth in mice bearing human esophageal xenografts without affecting body weight, white blood cell counts, or liver and renal function. Moscatilin also induced aberrant mitosis and apoptosis. Plk1 expression was markedly upregulated in vivo. Moreover, moscatilin pretreatment enhanced CE81T/VGH and BE3 cell radioresponse in vitro. Moscatilin may inhibit growth of human esophageal tumors and sensitize esophageal cancer cells to radiation therapy. View Full-Text
Keywords: moscatilin; human esophageal cancer; polo-like kinase 1; radiosensitization moscatilin; human esophageal cancer; polo-like kinase 1; radiosensitization

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Chen, W.-K.; Chen, C.-A.; Chi, C.-W.; Li, L.-H.; Lin, C.-P.; Shieh, H.-R.; Hsu, M.-L.; Ko, C.-C.; Hwang, J.-J.; Chen, Y.-J. Moscatilin Inhibits Growth of Human Esophageal Cancer Xenograft and Sensitizes Cancer Cells to Radiotherapy. J. Clin. Med. 2019, 8, 187.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top